This white paper explains why accelerating regulatory submissions with AI does not necessarily lead to faster approvals. MedTech and pharmaceutical organizations may increase output yet still face denials, delays, rework, and regulatory scrutiny when submissions lack clear data lineage, consistent evidence, and sufficient clinical or regulatory context. The paper distinguishes speed from velocity: speed is rapid production, while velocity combines speed with the right direction. It argues that patient-centric AI should operate within real-world regulatory frameworks, connect evidence to claims, and help teams produce clear, consistent, and defensible submissions. Applied effectively, AI can improve approval predictability, reduce risk, strengthen compliance, and help patients gain earlier

Join for free to read